For example, Tu et al. used CRISPR screening to identify genetic vulnerabilities in GBM-carrying telomerase reverse transcriptase (TERT) promoter mutations (TPMs), a genomic alteration present in over 80% of GBM cases [54]. This evidence concerns the gene TERT and glioblastoma.